Episode

Author Interview - Professor Andrew Cope, 2026

Podcast
The IMID Forum
Published
Mar 5, 2026
Duration seconds
1490
Processing state
not_requested
Canonical source
https://soundcloud.com/imidforum/author-interview-professor
Audio
https://feeds.soundcloud.com/stream/2277812666-imidforum-author-interview-professor.mp3
JSON
/v1/public/podcasts/the-imid-forum-981476/episodes/author-interview-professor-andrew-cope-2026
Markdown
/podcast/the-imid-forum-981476/author-interview-professor-andrew-cope-2026.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/author-interview-professor-andrew-cope-2026/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-imid-forum-981476/author-interview-professor-andrew-cope-2026.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.